Novel 1,5-Diphenylpyrazole Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors with Enhanced Activity versus the Delavirdine-Resistant P236L Mutant:  Lead Identification and SAR of 3- and 4-Substituted Derivatives

Clicks: 493
ID: 1021
2000
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #4 of 122 articles by views in Journal of medicinal chemistry

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 122 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Through computationally directed broad screening, a novel 1,5-diphenylpyrazole (DPP) class of HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) has been discovered. Compound 2 (PNU-32945) was found to have good activity versus wild-type (IC50
Reference Key
genin2000novel Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Genin, Michael J.;Biles, Carolyn;Keiser, Barb J.;Poppe, Susan M.;Swaney, Steven M.;Tarpley, W. Gary;Yagi, Yoshihiko;Romero, Donna L.
Journal Journal of medicinal chemistry
Year 2000
DOI
10.1021/jm990383f
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.